NCT07130604 - Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis | Biotech Hunter

Enrollment

390

Participants

Timeline

Start Date

September 26, 2025

Primary Completion Date

July 28, 2027

Study Completion Date

July 28, 2027

Conditions

Plaque Psoriasis

Interventions

DRUG

D-2570

Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-2570 group1, group 2 or placebo group.

DRUG

Placebo

Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-2570 group1, group 2 or placebo group.